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1. Introduction 
Iron is an essential element for the growth and development of all the scale of living 
organisms, and acquiring iron is crucial for the development of any pathogen. Iron 
participates in a large number of cellular processes, the most important of which are oxygen 
transport, ATP generation, cell growth and proliferation, and detoxification. It is a co-
enzyme or enzyme activator of ribonucleotide reductase, a key enzyme for DNA synthesis, 
which catalyzes the conversion of ribonucleotides to deoxyribonucleotidides and 
particularly of deoxyuridine to thymidine.1  
Iron is essential for both, the pathogen and the host, and complex mechanisms have evolved 
that illustrate the longstanding battle between pathogens and hosts for iron acquisition. The 
host has developed mechanisms to withhold iron from the microorganisms, thus preventing 
their growth, while the microorganisms have the capacity to adapt to the iron restricted 
environment by several strategies. Furthermore, iron modulates immune effector 
mechanisms, such as cytokine activities, nitric oxide (NO) formation or immune cell 
proliferation, and consequently, host immune surveillance.2 High levels of free iron may 
damage or destroy the natural resistance. It catalyzes the formation of highly reactive 
compounds, such as hydroxyl radicals, that cause damage to the macromolecular 
components of the cells, including DNA and proteins.3,4 Most environmental iron is in the 
Fe3+ state, which is almost insoluble at neutral pH. To overcome the virtual insolubility and 
potential toxicity of iron, ingenious transport systems and related proteins have evolved, to 
mediate balanced and regulated acquisition, transport, and storage of iron in a soluble, 
biologically useful, non-toxic form. The various proteins involved in mammalian iron 
transport and metabolism are presented in Table I. 
2. The role of iron in normal cell growth 
Iron holds an important metabolic role on the regulation of the cell cycle. It activates the 
cyclin/cyclin-dependent kinase complexes, favouring the progression to the S phase. 
Normally, all eukaryotic cells, entering the S-phase, upregulate transferrin receptor-1 
expression, to obtain iron from the extracellular environment. Low levels of intracellular 
Fe3+ increase cyclin-dependent kinase inhibitor p21CIP1/WAF1 levels, delaying or inhibiting the 
transition to the S-phase. As a result, Bcl-2 is down-regulated and Bax levels are increased, 
conditions that activate caspase-3, caspase-8, and caspase-9, and lead to apoptotic cell  
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Table 1. Proteins involved in iron transportation and metabolism. 
death.5 Therefore, unavailability of extracellular iron, and consequently intracellular iron 
deprivation, results in impaired DNA synthesis, and the cell cycle progression is arrested at 
the transition from G1 to S phase. Studying gene expression profile alterations in the HL-60 
cell line, it has been demonstrated that, under iron-deprived conditions 11 of 43 genes are 
>50% inhibited. These genes are Rb, p21WAF1/CIP1, bad, cdk2, cyclin-A, -D3, -E1, c-myc, egr-1, 
iNOS and FasL, all of which are essential for cell-cycle regulation and apoptosis.6 Apoptosis 
of the HL-60 cells, induced by iron deprivation, was not attributed to decreased bcl-2 or c-
myc expression, but to the activation of the cyclin-dependent inhibitor p21WAF1/CIP1.5,7 
However, although this metabolic step has long ago been recognized, it appears that 
additional key-points of cellular growth and development, exist, still vaguely known, which 
are controlled by intracellular iron and iron-containing proteins, since in some cases cell 
cycle arrest may also occur at the transition from the G2 to M phase.7  
Iron is highly toxic for biologic substrates, due to its high oxidative potential and its ability 
to generate Reactive Oxygen Species (ROS) according to the Haber-Weiss reaction: (O2- + 
H2O2 => HO + O2 + HO-).8 The major amount of intracellular iron is stored in ferritin, and 
the major cellular part of active iron implementation is the mitochondria. Iron is transported 
in the endomitochondrial space, with the assistance of the specific transporter mitoferrin 
and is stored in a specific type of ferritin, the mitochondrial ferritin.9 In the mitochondria, 
iron participates as coenzyme in the respiratory chains enzynes, the cytochromes, and in the 
formation of heme, which is incorporated in the other heme-containing proteins, 
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hemoglobin and myoglobin. In the cytoplasm iron is usually found in the endosomes, 
loosely bound with transferrin, and ready to be transported to specific substrates, in various 
as yet poorly-defined proteins and molecules and is stored in ferritin. All the sources of non-
ferritin bound iron are collectively defined by the term intracellular labile iron.10,11,12 
Iron is a major regulator of the cell cycle, by intervening with the formation and activity of 
the cyclin/cyclin-dependent kinase complexes. Depletion of intracellular iron by various 
iron chelators leads to cell cycle arrest, particularly in the G1 and the S phase, by producing 
an allosteric inhibition of cyclin-A, cyclin-E, and of cdc2 and cdk2. Moreover, it decreases 
intracellular levels of cyclin-D and cdk4 and changes retinoblastoma protein 
phosphorylation.13 In neuroepitheliomatous cells iron depletion reduces the expression 
particularly of the group D cyclins, and affects also negatively the expression of other 
cyclins.14 Iron chelators enhance the expression of several genes, involved in the down-
regulation of cell cycle progression, such as WAF1 and GADD45, in a p53-independent 
mechanism.15  In addition, cdc2 (p34) protein levels, which regulate the checkpoint of the 
G2/M phase transition, are decreased following incubation with iron chelators.16 A group 
from Sydney, Australia, specialized on iron metabolism has reported that iron depletion 
with deferroxamine (DFO) is associated with substantial decrease of cyclin D1 levels, 
through post-transcriptional modification of the protein, in a ubiquitin-independent 
manner, in contrast to what happens under normal conditions, in which cyclin D1 is cleared 
through proteasomal degradation.17 However, the expression of other cyclins, such as 
cyclin-E may be induced by iron deprivation, but since this cyclin form complex with cdk2, 
whose expression is down-regulated, the final result is again cell cycle arrest.16 
Excluding cyclins and cdks, many other cytoplasmic biological pathways are severely 
modified in relation to the concentration of intracellular iron. One of this is the 
retinoblastoma gene protein (pRb), which is a major regulator of the cell cycle. Under iron-
deplete conditions pRp is hypophosphorylated, an effect probably mediated by lactoferrin 
(Lf), and cell cycle is arrested. Lf is also a cell cycle regulator. In MCF-7 cells it induces Akt 
phosphorylation, which is followed by phosphorylation of pRb and of two G1-checkpoint 
Cdk inhibitors, p21Cip1/WAF1 and p27kip1.18 Hence the two inhibitors cannot cross nuclear 
membrane, remain in the cytoplasm and are degraded, whereas E2F transcription factor, the 
final inducer of the PI3K/Akt pathway, promotes the S phase entry. Lf-induced higher 
cytoplasmic localization of p21Cip1/WAF1 levels are abolished when cells are treated with the 
PI3K inhibitor LY294002. Thus Lf behaves as an antagonist of the Cdk inhibitors.19 
Other cell regulators, whose expression is influenced by the intracellular iron levels are p53 
and Hypoxia-Inducing Factor-1ǂ (HIF-1ǂ). Iron is a cofactor of the enzyme HIF-1ǂ prolyl 
hydroxylase, which down-regulates HIF-1ǂ activity. Under iron-deprived conditions 
intracellular HIF-1ǂ levels are increased, resulting in phosphorylation and stabilization of 
p53, whose levels are also increased. p53 in turn, induces transcription of the Cdk inhibitor 
p21Cip1/WAF1, with the previously mentioned consequences.20 Quercetin, a flavonoid 
antioxidant, strong metal chelator, increases and stabilizes HIF-1ǂ levels in normoxia and 
inhibits cell proliferation, predominantly by decreasing the concentration of intracellular 
iron.21 Αn additional cell cycle control system, influenced by the intracellular iron levels is 
accomplished by the cytochromes. In cells without a functional mitochondrial respiratory 
chain, and also in normal cells, quenching of mitochondrial ROS synthesis with MitoQ, the 
proliferation rate is delayed. In both cases important cell-cycle regulators such as cyclin D3, 
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cdk6, p18INK4C, p27KIP1 and p21CIP1/WAF1are reduced. Therefore, functional loss of 
mitochondrial electron transport chain inhibits cell-cycle progression, and this may occur 
through the decreased concentration of ROS, leading to down-regulation of p21CIP1/WAF1.22 
Finally iron appears to influence also the mRNA translational process. A Japanese group 
investigated the interaction of the multifactorial Y-box-binding protein (YB-1), with the iron-
regulatory protein-2 (IRP2) on translational regulation. Direct interaction of YB-1 and IRP2 
is taking place in the presence of high iron concentration. YB-1 reduces the formation of the 
IRP2-mRNA complex, and both, YB-1 and IRP2 inhibit mRNA translation. However, co-
administration of both proteins, abrogate the inhibitory effect of each protein alone. IRP2 
binds to YB-1, in the presence of iron and a proteasome inhibitor. The interaction of these 
two proteins demonstrate the involvement of YB-1 and of an iron-related protein in the 
translational regulation.23 The various intracellular signal pathways in which there is a 
known implication of iron are depicted in Table 2. 
 
Table 2. Intracellular signal transduction pathways in which iron is implicated. 
3. The role of iron in immune function 
Since the majority of the effector functions of the immune system rely on the rapid 
development and fast proliferation of the immunocompetent cells, and taking into account 
the strong influence of cell growth, proliferation and differentiation by intracellular iron 
levels, it is self-evident that iron would exert significant regulatory role on the immune 
system. Moreover, since iron plays also a crucial role for the growth and development of 
many pathogens, a large variety of cellular mechanisms, dedicated to both, microbial 
growth and host defense, are orchestrated, upon a combat for iron acquisition or iron 
deprivation.24  
The most primitive and less specific antimicrobial mechanisms of innate immunity are 
based on the development of proteins with high affinity to trivalent iron, such as transferrin 
(Tf) and Lf. These proteins are excreted by many cell types, but particularly by the 
neutrophils, to the extracellular space, bind iron from the circulating blood and tissues, thus 
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creating an environment not favoring pathogens’ growth. On the other hand, all pathogens 
elaborate specific iron-picking mechanisms from their environment, and in many instances 
also from the iron transporting proteins of the hosts, by synthesizing very high-affinity low 
molecular weight iron-chelators, the siderophores.  
Lf, in addition to its iron-depriving properties, exerts various direct antimicrobial, antiviral, 
antifungal and antiparasitic activities. By directly interacting with the cellular surface, Lf 
inhibits microbial and viral adhesion, and consequently prevents the entrance to the host 
cells, probably by interfering to various glycosaminoglycan-type receptors and viral 
particles. It also acts at later phases, impairing viral DNA insertion and replication.25 
Degradation of Lf by some proteolytic enzymes, leads to the formation of lactoferricin, 
which shares stronger antimicrobial activity and inhibits the growth of many pathogens, 
included multiresistant strains of bacteria and fungi. Both, Lf and lactoferricidin can prevent 
bacteremia, following food contamination of milk-fed animals with strong pathogenic 
bacteria or fungi (E.coli, Staph.aureus, C.albicans) and protect the intestinal mucosa from 
injury.26 Lf is also protective against the development of insult-induced Systemic 
Inflammatory Response Syndrome (SIRS) and its progression towards septic shock. This is 
accomplished through reduction or almost complete inhibition of the generation of 
intracellular and tissue oxidative stress, following LPS exposure, as measured by 
mitochondrial ROS expression, in a dose-dependent way. In vivo administration of Lf to 
experimental animals, significantly lowered LPS-induced mitochondrial dysfunction, 
estimated by decreased H2O2 release and mitochondrial DNA damage.27  
More striking was the clarification of the ability of stress hormones and inotropes, to 
stimulate the growth of pathogenic bacteria. Using electron paramagnetic resonance 
spectroscopy and chemical iron-binding analyses it was demonstrated that catecholamines 
form direct complexes with Fe3+, found within Tf and Lf. The formation of such complexes 
results in the reduction of Fe3+ to Fe2+ and the loss of protein-complexed iron. Both forms of 
iron, released from Tf or Lf is thereafter used as bacterial nutrient sources. Therapeutically 
relevant concentrations of stress hormones and inotropes in human serum could directly 
affect iron binding by Tf, so that the normally highly bacteriostatic tissue fluids may become 
significantly more supportive of the bacterial growth. The relevance of these catecholamine-
Tf/Lf interactions to the infectious disease process is under ongoing research.28 
Lf is also a very potent immunomodulator and anti-inflammatory protein.29 It recognizes 
specific microbial molecules/receptors, named Pathogen-Associated Molecular Patterns 
(PAMPs), which are LPS from the gram-negative cell wall, and bacterial unmethylated CpG 
DNA, acting either as a competitor for these receptors, or as a partner molecule, depending 
on the physiological status of the organism. By interacting with proteoglycans and 
membrane receptors of many cells of the innate- and adaptive immune system 
(lymphocytes, antigen-presenting cells, endothelial cells), Lf modulates the migration, 
maturation and function of these cells, and thus influences both arms of immunity.30 Bovine 
Lf attenuated Staphylococcal Enterotoxin B (SEB)-induced proliferation, IL-2 production and 
CD25 expression by transgenic mouse T-cells, an effect not induced through iron-
deprivation of staphylococci, but by lactoferricin. Cytokine secretion, following SEB-
stimulation by T-cell lines and by normal peripheral blood mononuclear cells, was also 
inhibited by Lf, suggesting a possible therapeutic applicability of this protein.31 When given 
orally, Lf is easily uptaken by enterocytes, but also by the CD3+ lymphocytes of the lamina 
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propria and the small intestinal submucosal tissue, and is mainly distributed in the cytosol. 
However, occasionally, it may also be distributed in the nucleus, suggesting that it might 
exert a direct regulatory role.32 
Similar immunoregulatory properties have been postulated for Tf, which plays an essential 
role for normal T-lymphocyte growth and early differentiation. The absolute number of T-
cells has been found substantially reduced in hypotransferrinemic Trfhpx/hpx mice, and this 
could not be attributed to increased apoptosis. Moreover, the differentiation of CD4-CD8-
CD3-CD44-CD25+TN3 into CD4-CD8-CD3-CD44-CD25-TN4 cells was impaired, and a 
similar impairment of early T-cell differentiation was observed in mice with reduced levels 
of Tf receptor.33 
The iron chelator DFO arrests cell cycle progression in activated T lymphocytes in the late 
G1 phase, before the G1/S border, by inhibiting transcription of the cdc2 gene, but has no 
effect on accumulation of cdk2, cdk4, or IL-2-transcripts. p34/cdc2 protein complex becomes 
undetectable, whereas synthesis of the p33/cdk2 protein begins and is activated as an H1 
histone kinase, but this complex is insufficient to complete the G1 phase. Synthesis and early 
accumulation of cyclin E and cyclin E-dependent kinase are not affected by DFO, but cyclin 
A and cyclin A-dependent kinase are inhibited, although cyclin-A mRNA levels remain 
normal. Thus, DFO blocks cell cycle progression, through inhibition of cyclin A appearance, 
which is a major component of the p33/cdk2 complex.34 DFO but not ferrioxamine (iron 
saturated DFO) inhibits growth and proliferation of the Jurkat T-cell line at the G0/G1 
transition and induces apoptosis. However, iron-loaded Jurkat cells are not arrested. Silybin, 
a flavonoid antioxidant, free radical scavenger, acting also as iron chelator, shows a bimodal 
effect, inducing cell proliferation at low-, and DNA synthesis inhibition and apoptosis at 
high concentrations. The effect of silybin on the growth and viability of iron-loaded cells 
was similar to that of its iron complex, implying that the biological effects of silybin are 
different than those of DFO, and it probably shares pro-oxidant effect, via iron-catalyzed 
oxidation and generation of ROS.35 
The high frequency of infections, reported in hemodialysis patients, when receiving 
intravenous (IV) iron preparations, revealed that IV iron administration is associated with 
time-dependent increases of the intracellular oxidative stress in many immunocompetent 
cell populations, resulting in dysfunctional cellular immunity. The CD4+ lymphocytes are 
mainly affected, with a statistically significant reduction in their survival after incubation 
with all doses of iron preparations. IV iron products induce also various deleterious effects 
on CD16+ lymphocyte populations, which may also be mediated by intracellular ROS 
formation.36 
Iron tetrakis (N-methyl-4'-pyridyl-porphyrinato: FeTMPyP) is a potent antiinflammatory 
and scavenger of ROS. Treatment of thymocytes with FeTMPyP results in the inhibition of 
various mitogen-or cytokine-induced proliferation signals, and of the DNA-binding activity 
of NF-κB and IL-2 secretion. Inhibitors of p38-MAPK and of the ERK protein block the 
growth and proliferation of ConA-stimulated thymocytes, the NF-κB activation and IL-2 
secretion.37 Interferon regulatory factor-1 (IRF1) regulates the expression of genes involved 
in the inflammatory response and cell cycle control. IRF1 expression is transcriptionally 
mediated by TNF-ǂ or IFN-Ǆ, via iron-dependent pathways and is inhibited when cells are 
pretreated with iron chelators. Addition of exogenous iron reconstitutes cytokine 
responsiveness, indicating that iron is the target for the chelator effect.38 
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In addition to Lf, ferroportin (Fp), an iron efflux protein, strongly influences host response 
to infection. Murine macrophages overexpressing Fp show impaired intracellular 
M.tuberculosis killing at early stages of infection. When challenged with LPS or M.tuberculosis 
infection, control macrophages increase NO synthesis, but macrophages overexpressing Fp 
had significantly reduced NO and iNOS mRNA and protein production, thus limiting the 
bactericidal activity of these macrophages. IFN-Ǆ reversed the inhibitory effect of Fp on NO 
production, findings suggesting a role for Fp in attenuating macrophage-mediated immune 
response.39 Hepcidin, the allosteric inhibitor of Fp, regulates intracellular iron levels by 
interacting with, and promoting Fp degradation. All immunoregulatory cells express 
hepcidin mRNA; hepcidin mRNA expression increases after T-lymphocyte activation and in 
response to holotransferrin (Fe-Tf) or ferric citrate challenge. Therefore, low hepcidin 
expression impairs normal lymphocyte proliferation.40 
Normal tissue macrophages are polarized, through the action of cytokines, into classically- 
(M1) and alternatively-activated (M2). M1 macrophages have low IRP-1 and -2 binding 
activity, express high levels of H-ferritin, low levels of Tf receptor-1 and internalize iron, only 
at high extracellular concentrations. Conversely, M2 macrophages have high IRP-binding 
activity, larger intracellular labile iron pool, express low levels of H-ferritin and high levels of 
Tf receptor-1, and effectively internalize and release iron, even at low concentrations. Iron 
export correlates with Fp expression, which is higher in M2 macrophages. In the absence of 
iron, only M1 macrophages are effectively activating antigen-specific, MHC class II-restricted 
T cells. Thus finally, cytokines control iron handling, by differentiating macrophages into a 
subset with relatively-low intracellular iron content (M1), or a relatively-high iron containing 
subset, endowed with the ability to recycle iron (M2).41 Besides the classical mechanisms of 
antimicrobial activity (peptidic antibiotics, induction of oxidative stress, leading to respiratory 
burst) macrophages can deprive intracellular pathogens of necessary nutrients, and most 
importantly of iron. Moreover, according to the type of phagocytized pathogen, they can 
modulate, even the extracellular environment, impeding pathogens the access to essential 
nutrients. Thus various membrane transporters may remove nutrients from vacuolar 
compartments, degrade growth factors, and sequester other molecules, important for 
microbial growth, in a way similar to iron deprivation.42 
Iron deficiency has been associated with various immune abnormalities, and particularly 
with impaired lymphocyte proliferation. T-cells from iron deficient mice exhibit poorer 
monocyte stimulatory activity following Con-A activation, as estimated by CD80 and CD86 
expression on antigen presenting cells. The addition of DFO increased the expression of 
both markers on resting B and T cells. Lymphocyte proliferative responses to mitogens 
correlated positively with CD80 and CD86 expression, but negatively with the percentage of 
CD80+ cells. Therefore, the impaired lymphocyte proliferation of iron deficiency cannot be 
attributed to reduced CD80 and CD86 expression.43 
The immunoregulatory properties of ferritin include binding to T lymphocytes, suppression 
of the delayed-type hypersensitivity and of antibody production by B lymphocytes, and 
impairment of phagocytosis by the granulocytes. 
4. The role of iron in inflammatory and neoplastic diseases 
Iron plays a major role in the generation and perpetuation of inflammatory processes. Many 
chronic inflammatory diseases are directly influenced by the intracellular and extracellular 
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iron concentrations. Disease activity, and particularly the manifestation of serositris and 
various hematological disturbances in rheumatoid arthritis, systemic lupus erythematosous, 
Still’s disease, dermatomyositis, and other collagen diseases are strongly correlated with 
serum and tissue ferritin levels.44,45 Ferritin and iron homeostasis are implicated in the 
pathogenesis of many other disorders, including atherosclerosis, Parkinson’s disease, 
Alzheimer disease, and restless leg syndrome. Iron contributes to the synthesis of myelin, 
and severely iron deficient patients exhibit impaired myelin formation. In patients with 
multiple sclerosis, serum and cerebrospinal fluid levels of Tf and ferritin levels have been 
found significantly elevated only during progressive active disease.46 Brain tissue of patients 
with multiple sclerosis exhibits abnormal distribution of Tf and ferritin.47 Ferritin binding to 
the inflammatory lesion and the immediate periplaque region within the white matter is 
practically absent, but returns to normal as the distance from the lesion increases. Therefore, 
the loss of ferritin binding is correlated with demyelination, accompanying multiple 
sclerosis.48 Reactive Oxygen Species participate in the pathogenesis of allergic 
encephalomyelitis, whereas the infusion of apoferritin in experimental animals may induce 
a remission status.49 Thyroid hormone upregulates ferritin genes’ expression, and elevated 
serum ferritin levels have been reported in patients with subacute thyroiditis, which were 
correlated with disease activity. These levels were higher, as compared to patients with 
Graves’ disease and Hashimoto’s thyroiditis.50 
Ferritin synthesis is regulated by the main proinflammatory cytokines (TNF-ǂ, and IL-1ǂ) at 
various levels (transcriptional, post-transcriptional, translational) during cellular 
development, differentiation and inflammation. Cytokine-induced cellular response to 
infection by various pathogens includes the upregulation of ferritin genes. Translation of 
ferritin is induced by IL-1ǃ, IL-6 and TNFǂ, and iron is required for this regulation. Ferritin 
is accumulated in macrophages during various inflammatory conditions, when serum iron 
levels are decreased, leading to the formation of ferritin molecules with high content of 
iron.51  
High heme oxygenase-1 (HO-1) expression, elevated ferritin accumulation in renal tubules 
and increased iron deposition in renal proximal tubules have been reported in patients with 
immunohemolytic anemia.52 HO-1 degrades heme to biliverdin, carbon monoxide and free 
iron. HO-1 expression is induced among others, by proinflammatory cytokines and high 
intracellular ROS levels. This enzyme appears to have significant immunoregulatory 
properties, acting as inhibitor of immune reactions and participating in the pathogenesis of 
many inflammatory, infectious, allergic and autoimmune diseases and conditions, and has 
been proposed as a possible target inducing immunosuppression in allogeneic stem cell 
transplantation.53 
Besides the stimulatory role on DNA synthesis, iron interferes with cell proliferation, by 
enhancing c-myc expression. Regulation of c-myc expression is crucial for the maintenance 
of cellular homeostasis. Overexpression or abnormal intracellular localization of c-myc 
results in the activation and deregulation of this oncogene. Surprisingly, when added to 
Burkitt's lymphoma cell lines, iron markedly inhibits cell proliferation, through cell cycle 
arrest in the G2/M transition, followed by a significant decrease in c-myc expression. A 
similar effect is not observed in cell lines with constitutive c-myc expression. Down-
regulation of c-myc, which is independent from cell cycle blockade, leads to apoptotic cell 
death, implying the existence of another iron-dependent cell cycle regulatory mechanism, 
involving modulation of c-myc expression.54 
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Antisense oligodeoxynucleotide treatment against H- and L-ferritin chains increased the 
steady-state labile iron pool and the production of ROS after oxidative challenges and 
down-regulated Tf receptors, whereas it had no effect on the long-term growth of the cells. 
However, repression of ferritin synthesis facilitated renewal of the growth and proliferation 
of cells pre-arrested at the G1/S phase. Renewed cell growth was significantly less 
dependent on external iron supply, when ferritin synthesis was repressed, and its 
degradation was inhibited by lysosomal antiproteases.55 
5. Iron and bacterial infections 
Bacteria are confronted with a low availability of iron owing to its insolubility of the Fe3+ 
form, or its binding to host proteins. Free iron concentration in the host environment is 
about, or lower than 10-15M and in some instances as low as 10-24. Bacteria and other 
microorganisms need powerful and sophisticated mechanisms to acquire iron. Iron 
availability is a signal, alerting pathogenic bacteria, when they enter the hostile 
environment. When bacterial pathogens infect a host, cytotoxins damage the host cells 
releasing ferritin, hemolytic toxins lyse erythrocytes releasing hemoglobin, and Lf is 
produced by neutrophils and epithelial cells. The bacteria cope with the iron deficiency, by 
developing various uptaking systems: siderophores (low-molecular weight substances, with 
very high affinity for iron), systems for free heme and heme bound to hemoproteins 
(hemoglobin, hemoglobin-haptoglobin, heme-albumin, heme-hemopexin) and siderophore-
based mechanisms to acquire iron from the iron-binding proteins Tf and Lf.   
Pathogens encounter a period of iron starvation, upon entering their host and they sense 
alterations of the iron status, via the Ferric Uptake Regulator (FUR). The FUR protein plays a 
key role in the transcriptional response to iron of Escherichia coli and other gram-negative 
bacteria. The mechanism of action of FUR is repression of siderophore production and iron 
transport promoters. When iron is limiting, FUR protein is inactive as a repressor. This 
results in derepressed transcription of genes, involved in siderophore synthesis, and high-
affinity iron uptake. FUR homologues are present in many bacteria.56 In addition heme-
sensing systems have been evolved by many pathogens, like Staphylococcus aureus, Bacillus 
anthracis, and Corynebacterium diphtheriae. For instance, S. aureus is able to sense heme 
through the heme sensing system (HssRS), two-component system that detect the presence 
of toxic levels of exogenous heme. Upon sensing heme, HssRS directly regulates the 
expression of the heme-regulated ABC transporter HrtAB, which alleviates heme toxicity.57 
In some halophilic bacteria, such as Chromohalobacter salexigens, iron homeostasis is coupled 
to the reaction to osmotic stress, through the activity of FUR. A decrease in iron and 
histidine requirements and a lower level of siderophore synthesis were observed at high 
salinity.58 
Siderophores (named after the Greek word for iron carriers) are low molecular weight iron-
binding complexes, produced and secreted by bacteria, fungi and plants. These molecules 
target ferric iron (Fe 3+), the form of iron found in well oxygenated environment in the host.  
Based on the metal chelating group, there are three major classes of microbial siderophores, 
the catecholate, the hydroxycarboxylate and the hydroxamate class. These substances 
exhibit extremely high affinity for iron, and hold it with three bidentate bonds. The high 
affinity is specific for iron, and does not extend to other bivalent cations. Siderophore 
production is enhanced in conditions of iron starvation, and many metabolic steps of their 
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biosynthesis have been characterized. Siderophores have higher binding constants for iron, 
than do Tf and Lf, and thus are capable of detaching iron from these proteins. Their 
biosynthesis is confined to bacterial and fungal cells, and their expression increases the 
virulence of these species.59 The most commonly encountered siderophores are described in 
Table 3.  
 
Table 3. The major microbial sideropophores. 
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Iron loaded siderophores bind to cognate receptors, expressed at the bacterial surface. In 
gram negative bacteria, there is an outer membrane, external to a very thin (1-nm) 
peptidoglycan layer. Peptidoglycan is the structure that confers cell wall rigidity and 
resistance to osmotic lysis, in both, gram positive- and gram negative bacteria. In gram 
positive bacteria peptidoglycan is the only layered structure external to the cell membrane 
and is thick (20-80 nm). In gram negative bacteria the ferric-siderophores use outer 
membrane transporters, because they are large enough to pass through the porins (the small 
pores in the bacterial outer membrane that allow passive diffusion of molecules with 
molecular weight <600 Da).60 The energy for the transport of these ligands across the outer 
membrane is delivered from the inner membrane, by a complex of three cytoplasmic 
membrane proteins TonB, ExbB, and ExbD.61,62 TonB spans the periplasm, contacts outer 
membrane transporters by its C-terminal domain, and transduces energy from the proton 
motive force to the transporters. There is no need for TonB-ExbB-ExbD complex and outer 
membrane trasporters in gram-positive bacteria, as there is no outer membrane. Each class 
of siderophore is shuttled by a specific periplasmic binding protein (PBP) to the inner 
membrane. For example, FhuD is a siderophore binding PBP with a well-determined 
structure, found in gram negative and gram positive bacteria.63 When iron-replete 
siderophores arrive at the microbial cytoplasmic membrane, they are taken up across the 
membrane by periplasmic binding protein-dependent ABC transporters in an ATP-
dependent process. ABC trasporters comprise of two transmembrane domains forming a 
channel for the siderophore, to pass through and two nucleotide binding domains that 
hydrolyse ATP. The complex is internalised into the bacterium and the iron is released by 
proteolysis or by the action of enzymes that reduce Fe3+.  Fe2+ is incorporated into 
metalloenzymes or stored in bacterioferritin or in the related Dps proteins. The genes for 
siderophore biosynthesis and transport are usually under transcriptional control in response 
to the cellular pool of iron. 
At the site of infection, leukocytes secrete siderocalin (also called lipocalin-2, neutrophil 
gelatinase-associated lipocalin). Siderocalin is also produced by epithelial cells and 
macrophages. Upon encountering invading bacteria, the Toll-like receptors on immune cells 
stimulate the transcription, translation and secretion of siderocalin. Secreted siderocalin then 
binds to ferric-siderophore complexes, participating in the antibacterial iron depletion 
strategy of the innate immune system.64,65,66 However, pathogens produce structurally 
modified enterobactin-type siderophores, that are resistant to siderocalin and are known as 
stealth siderophores.67 The first glucosylated siderophore described was salmochelin, a C-
glucosylated enterobactin produced by Salmonella species, uropathogenic Escherichia coli 
strains, and some Klebsiella strains.68  
Except of siderophores, gram positive and gram negative bacteria may use free heme or 
heme bound to host hemoproteins as iron source.69,70 Like siderophores, this iron uptake 
pathway includes a TonB-dependent outer membrane receptor, while the transport across 
the cytoplasmic membrane requires periplasmic and inner membrane proteins comprising 
the ABC systems, which utilize the energy derived from ATP hydrolysis.71 In addition, 
bacteria elaborate hemophores which are molecules that can remove heme from host 
hemoproteins. Bacterial hemophores are secreted to the extracellular medium, where they 
scavenge heme from various hemoproteins, due to their higher affinity for this compound, 
and return it to their specific outer membrane receptor.72 An example is Serratia marcescens, 
that secretes a heme-binding protein, HasA, which functions as a hemophore that catches 
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heme and shuttles it to a cell surface specific outer membrane receptor, HasR. The HasR 
receptor belongs to the TonB-dependent family of outer membrane receptors. HasAp, a gene 
from Pseudomonas aeruginosa has been isolated. HasAp is an iron-regulated extracellular 
heme-binding protein that shares about 50% identity with HasA and is required for P. 
aeruginosa utilization of hemoglobin iron.73  
Pathways analogous to those described above are also utilized in gram-negative bacteria, for 
the uptake of iron from the iron-binding proteins Tf and Lf. Lf and Tf receptors are present 
in pathogenic bacteria.74 Iron must be stripped away from Lf and ferritin prior to be 
transported into the bacterial cell. Two proteins, Tf-binding protein A (TbpA) and Tf-
binding protein B (TbpB), function like the Tf receptor in many pathogenic bacteria, such as 
Neisseria meningitides. The expression of these genes is induced along with several other 
proteins under iron-restricted conditions.70 Lf-binding protein A (LbpA) and Lf-binding 
protein B (LbpB) have been identified as outer membrane receptors for Lf. The extracted 
iron is then transfered into the periplasm. Within the periplasm, the ferric ion is complexed 
by ferric ion-binding protein A (FbpA). FbpA shuttles the iron to an inner membrane 
complex consisting of two proteins, the inner transmembrane FbpB and the cytoplasmic 
ATPase FbpC, finally transported into the cytoplasm. 
Pseudomonas aeruginosa produces 2 siderophores under iron-limiting conditions, pyoverdine 
and pyochelin. Vanadium a rare metal, and probably other metallic ions, form complexes 
with both of these siderophores and strongly inhibit P.aeruginosa growth. Pyoverdin-
deficient mice were more sensitive to vanadium, whereas pyochelin-negative mutants were 
more resistant. V-pyochelin strongly inhibits pseudomonas growth, increasing the activity 
of Superoxide Dismutase by about two times. Therefore, it appears that V-pyochelin 
catalyses a Fenton-type reaction, in which superoxide anion O2- is generated, and vanadium 
compromises pyoverdin utilization.75 However, in some pyoverdin deficient strains another 
siderophore molecule was identified, and this is quinolobactin. Its receptor is the 75-kDa 
iron-repressed outer membrane protein (IROMP) and the quinolobactin-mediated iron 
uptake system functions only in the absence of pyoverdine, and is repressed by 
pyoverdine.76 Multicopper ferroxidases are enzymes that oxidize Fe2+ to Fe3+ in the 
microbial environment, so that iron will be transformed in a less active form, easily 
uptakable by microbial siderophores. Ps. aeruginosa possesses such an enzyme. Mutant 
strains are unable to grow with Fe2+ as iron source, because they cannot uptake iron. Thus 
multicopper ferroxidase represents another iron acquisition mechanism, important for 
virulence and pathogenicity of many bacteria.77 
Some strains of Vibrio anguillarum produce a catechol-type siderophore named 
vanchrobactin, whose biosynthesis is under complex regulation, in an effort to adjust its 
production according to environmental iron concentrations.78 
Although iron is important for all the scale of microorganisms, some types are less strictly 
dependent on iron than others. Moreover, growth characteristics and virulence of 
intracellular pathogens may vary, according to the type of infected cells. Chlamydia 
pneumoniae is an intracellular bacterium, causing chronic inflammatory disease in humans. 
When endothelial cells and monocytes were infected with C.pneumoniae, supplemented with 
iron and then stimulated with IFN-Ǆ, iron had no significant effect on Chlamydia growth 
within monocytes, whereas on endothelial cells iron enhanced its proliferation and 
differentiation, and IFN-Ǆ had an inhibitory effect. C.pneumoniae infection induced a pro-
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inflammatory immune response in monocytes, but not in endothelial cells and Chlamydia 
remains in a persistent-latent form within monocytes but it differentiates and proliferates 
within endothelial cells.79 
Various drugs may interfere with the microbial-host battle for iron acquisition. The calcium 
channel blocker nifedipine enhances host resistance against intracellular pathogens, by 
restricting iron availability. In a murine macrophage cell line, nifedipine significantly 
reduced intracellular bacterial survival of Salmonella Typhimurium and Chlamydophila 
pneumoniae. Moreover, in mouse models of iron overload, nifedipine was capable of 
mobilizing tissue iron. When these mice were infected intraperitoneally with Salmonella, and 
subsequently treated with nifedipine for 3 consecutive days, bacterial counts in livers and 
spleens were significantly reduced and survival was prolonged, compared with placebo-
treated animals. Nifedipine increased Fp expression in the spleen, whereas splenic levels of 
ferritin and serum iron concentrations were reduced. Therefore, nifedipine, and probably 
other drugs, may induce Fp expression, export iron from macrophages and thus restrict iron 
availability for intracellular pathogens.80 
The Brucella spp are facultative intracellular pathogens. The two predominant host cell types 
inhabited by Brucella are macrophages and placental trophoblasts. These bacteria produce 
2,3-dihydroxybenzoic acid (2,3-DHBA) in response to iron limitation in vitro, which 
functions as a siderophore.81 In addition, Brucella abortus strain 2308 produces brucebactin, a 
more complex 2,3-DHBA-based siderophore.82 It has been showed that these siderophores 
are not required for wild-type replication of B. abortus in cultured murine macrophages. 
Paulley et al showed that heme is an important iron source for the bacterium, during 
chronic infection. Heme has a key role during the stationary phase, allowing Brucella to 
maintain intracellular residence in host macrophages. Recent analysis of the known Brucella 
genome sequences revealed a homolog of the heme transporter shuA gene of Shigella 
dysenteriae and has been given the designation bhuA (Brucella heme utilization).83,84 The gene 
encodes a TonB-dependent outer membrane heme transporter. In Brucella spp the genes 
involved in the transport of heme across the cytoplasmic membrane are located in an operon 
distant from the bhuA locus.85 In other gram negative bacteria, the genes for the periplasmic 
binding protein-dependent ABC transporter, responsible for the transportation of heme 
across the cytoplasmic membrane, are located in an operon with the gene for the TonB-
dependent outer membrane transporter. 
6. Iron and mycobacterial infections 
Mycobacterium tuberculosis (Mtb) has developed various means of attacking the host system. 
One such crucial strategy is the exploitation of the iron resources of the host system. When 
Mtb evade the mammalian immune system, it resides within macrophages in an early 
phagosome, whose maturation to the late phagosome and phagolysosome stages is blocked. 
The control of the intraphagosomal environment is crucial. Macrophages digest senescent 
erythrocytes and degrade heme, thus accumulating iron. Iron mainly egresses the 
macrophage bound to Tf, although a part of it is incorporated into ferritin in the cytosol. 
Other main iron sources for the macrophage are the hemoglobin-haptogobin complex, taken 
up via the hemoglobin scavenger receptor CD163 during hemolysis, and iron bound to Tf 
and Lf that enters macrophages, via the transferrin-transferrin receptor and lactoferrin 
receptor pathway, respectively.71 Iron is exported from the cell via Fp-1 which is the 
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receptor for hepcidin. In the presence of inflammation serum hepcidin is high and the 
binding to Fp induces conformational changes to this molecule, resulting in allosteric 
inhibition of its function, thus halting iron egress, and promoting internalization and 
degradation of Fp.86,87   
Within its phagosome, Mtb acquires iron from the cytoplasmic sources or from the Tf/Tf-
receptor complex.88 By the time Mtb faces the low-iron environment of the phagosome, 
several Mtb genes, involved in the biosynthesis of siderophores, are induced. There is a dual 
mycobacterial siderophore system, made of mycobactins, the water-soluble 
carboxymycobactin, and the lipophilic mycobactin-T, which transfers iron captured by the 
hydrophilic carboxymycobactin, across the cell wall.89 Mycobactin, except from participating 
in iron internalization, it prevents sudden influx of excess iron, when the metal becomes 
available. For the transportation across the cell membrane, a reductase converts Fe3+-
mycobactin to the Fe2+ form. The ferrous ion, possibly complexed with salicylic acid, is then 
shuttled across the membrane, either for direct incorporation into various porphyrins and 
apoproteins, or for storage of iron within the bacterial cytoplasm. The overall process of iron 
acquisition and utilization requires the activation of a number of mycobacterial genes. Mtb 
contains four potential iron-dependent regulators, belonging to two different families of 
metalloregulatory proteins. Two genes, furA and furB, encode proteins, belonging to the 
FUR family. The other two genes, IdeR and SirR are members of the DtxR (diphtheria toxin 
repressor) family. IdeR is an essential regulator with a major role in controlling iron 
metabolism, by repressing siderophore production, activating iron storage genes and 
positively regulating oxidative stress responses.90 In Mtb-infected macrophages an 
upregulation of IdeR was found as part of the bacterial protective mechanism against iron-
mediated oxidative stress. 
Immune cell derived mediators control systemic and cellular iron homeostasis. On the other 
hand, iron affects the activity of transcription factors related to immune responses, and 
therefore, the secretion of cytokines.91 Iron, directly inhibits the action of IFN-Ǆ, which is 
crucial for the control of intracellular infections. In iron-loaded macrophages, an inhibition 
of IFN-Ǆ mediated pathways is noted while intraphagosomal Mtb growth is stimulated.92 
However, IFN-Ǆ activation of human monocytes decreases iron availability to Mtb.93 Sow et 
al. examined the expression of hepcidin in macrophages, infected with Mycobacterium 
avium and Mtb and found that IFN-Ǆ induced high levels of hepcidin mRNA and protein by 
pathways involving STAT1 activation and Toll-like receptors TLR2 and TLR4.94,95 
Dietary iron overload, mainly in rural populations in sub-Saharan Africa, causing iron 
overload of macrophages and hepatocytes may increase the risk of tuberculosis. The 
incidence of tuberculosis has markedly increased the last decades, primarily as a result of 
the infection with the human immunodeficiency virus (HIV). Acquired immunodeficiency 
syndrome (AIDS) patients exhibit alterations in iron metabolism that lead to increased 
deposition of this element in the tissues. Such alterations may underlie the increased 
susceptibility of AIDS patients to mycobacterial infections. Many ongoing studies are 
aiming to investigate the Mycobacterial iron-acquisition pathways and their role in the 
treatment of tuberculosis e.g. synthesizing selective inhibitors of iron metabolism that may 
be helpful as chemotherapeutic agents. Table 4 resumes the most commonly encounterd 
iron uptaking mechanisms, during bacterial growth. 
www.intechopen.com
 




Table 4. Summary of the most common iron upatking mechanisms elaborated by pathogens. 
7. Iron and fungal infections 
The larger proportion of systemic fungal infections are opportunistic i.e. an important factor 
for their occurrence is a background of primary or secondary (in the majority of cases 
iatrogenic) immunosuppression. For all fungal pathogens iron is essential for many 
metabolic processes and the most intelligent and complex systems of iron acquisition from 
the host cells and tissues, is found among various fungal strains. Particularly for fungi, iron 
is a major virulence factor.96 Many if not all, host-developed mechanisms of host defence 
against pathogenic fungi are orchestrated through iron deprivation. Lf, produced and 
released mainly by neutrophils and monocytes, represents the major fungistatic factor of 
human serum, milk and other fluids.97  
Fungal pathogens require 10-7 to 10-6 M iron for their growth, and, therefore, serum and 
other biological fluids and tissues, containing <10-15 and as low as 10-24 M of iron are 
normally fungistatic for all species, including Candida, Aspergillus and Zygomycetes.98 The 
fungistatic properties of human serum are completely abolished by the in vitro addition of 
exogenous iron, and Candida albicans can grow in serum cultures with Tf saturation >90%, 
but not in serum with normal Tf saturation. Diseases and conditions, accompanied by a high 
iron burden have been associated with increased susceptibility to fungal infections. Among 
these are tissue hypoxia, diabetic ketoacidosis, acidosis of any other cause, tissue damage 
and necrosis, post-traumatic states or those induced by chemotherapy, hemochromatosis, 
liver disease and cancer. Patients with acute myelogenous leukemia or other hematologic 
malignancies have commonly an excess of iron, and particularly, non-transferrin-bound 
iron, which is further increased following chemotherapy,99 either because of tissue damage 
or, in some cases, as a result of circulating iron complexes. Such complexes are produced by 
the leukemic cells and are liberated following their death, induced by chemotherapy. All the 
above, render leukemic neutropenic patients particularly vulnerable to fungal infections. 
Liver iron overload, in patients undergoing orthotopic liver transplantation, is also a 
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predisposing factor for the development of invasive fungal infections, and such infections 
occur almost three times more commonly among transplanted patients with elevated levels 
of iron in the liver.100  
Iron uptake by fungi is accomplished by specific transport systems, in which an initially Fe3+ 
form is reduced to Fe2+ iron, through the action of specific cell surface reductases 
(ferroxidases). Ferrous iron is then internalized by three different mechanisms. The first is 
achieved thank to the high affinity of the iron-containing ferroxidases for a specific type of 
fungal transport proteins, named permeases. The iron permease-ferroxidase complexes 
(Ftr1-Fet3) easily transverse the fungal wall and cell membrane, and iron is thereafter 
provided intracellularly. There are three types of specific transcriptional activators or 
repressors of the genes encoding ferroxidases and permeases, which modulate their 
expression under iron-deprived conditions: the Aft1 and Aft2 activators in Saccharomyces 
cerevisiae and other yeast, or the Cryptococcus iron regulator gene (CIR1) in Cryptococcus 
neoformans, the GATA-type repressors, such as Sfu-1, present in many fungal species and the 
HapX/Php4 in Schizosaccharomyces pombe and Aspergillus species. A second mechanism or 
iron acquisition involves the production of siderophores, which are excreted through the 
fungal wall in the deferric form, bind iron, and then are taken up by the fungi. Finally, a 
third mechanism is related to a fungal heme oxygenase, which takes up iron from 
heme.101,102  
C. albicans possesses two high-affinity iron permease genes that are essential for its 
virulence. Iron permeases are encoded by iron-responsive genes, which are regulated by the 
specific transcriptional activator Hap43 and the repressor Sfu1. Deletion of these genes 
renders mutant strains non-virulent.103 Various iron overload conditions enhance C. albicans 
growth and increase the mortality rate of infected mice. Elevated serum iron levels have 
been documented among patients with urogenital candidiasis. In C. albicans CIR1 is a gene 
regulating iron homeostasis, as well as calcium and cAMP signaling, cell wall integrity, and 
the expression of all virulence functions, including capsule and melanin formation and 
growth at host temperature. Hap43 protein is essential for the growth and virulence of 
C.albicans under low-iron conditions, and is accumulating in the nucleus. Hap43 is not 
required for iron acquisition, but it is responsible for repression of genes encoding iron-
dependent proteins involved in mitochondrial respiration and iron-sulfur cluster formation. 
There is an association between Hap43 and the global corepressor Tup1 in response to iron 
deprivation.104  
Sit1 is a combined siderophore-iron transporter, found in C. glabrata. For this yeast iron 
acquisition is necessary, not only for the growth and virulence, but also for maintaining its 
survival against the fungicidal activities of macrophages. Within the Sit1 transporter, a 
conserved extracellular SIderophore Transporter Domain (SITD) has been identified, that is 
critical for the ability of C. glabrata to resist macrophage killing. C. glabrata senses altered 
iron levels within the phagosomal compartment and Sit1 functions as a determinant of 
survival in a way that is dependent on the iron status inside the macrophage.105 
Non-enzymatic reduction of ferric iron by 3-hydroxylanthranilic acid and melanin has been 
documented in Cryptococcus neoformans.106 The expression of permease genes in Aspergillus 
and zygomycetes is upregulated during their growth and virulence.107 The growth, survival 
and virulence of Aspergillus fumigatus and other mold species in serum is associated with the 
removal of iron from Tf and other iron-containing proteins.108 This is accomplished by 
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siderophores. HapX, a bZIP-type transcriptional regulator, is a very important gene, which 
sets up the adaptation mechanism to iron starvation in A. fumigatus. HapX represses all iron-
dependent and mitochondrial-orchestrated metabolic activities, including respiration, TCA 
cycle, amino acid metabolism, iron-sulfur cluster formation and heme biosynthesis. Iron 
starvation induces significant modulation of the amino acid pool and HapX coordinates the 
production of siderophores and their precursor amino acid ornithine. HapX activity is 
restricted to iron-deplete conditions, therefore, HapX-deficiency causes significant 
attenuation of virulence in a murine model of aspergillosis.109 
Fungal species are capable of synthesizing many different siderophores; however, the most 
important and most commonly found in Aspergillus and zygomycetes are N’’,N’, N-
triacetylfusarinine C and ferricrocin. Aspergillus uses two iron uptake mechanisms, the 
reductase-permease complex and the siderophore-assisted mechanism.110 The latter has 
been demonstrated in vitro, as holotransferrin, but not apotransferrin, supports the growth 
of Aspergillus spp. in iron-depleted serum culture systems. In such systems, siderophore 
production becomes evident following 10 h of incubation and reaches a peak at 20 h.105 
Nevertheless, not all species and strains produce siderophores. Some fungi use ferric 
reductases or low molecular mass iron reductants, to reduce ferric to ferrous iron, and 
extract it from the extracellular environment. Such mechanisms have been documented in C. 
albicans, Histoplasma capsulatum,111 and in Cryptococcus neoformans.112 
7.1 Iron metabolism in Zygomycetes 
Zygomycosis is a difficult-to-treat systemic fungal infection, caused by the zygomycetes, and 
is associated with a high mortality rate, ranging from 50% to 100%. Rhizopus oryzae is the 
most common cause of zygomycosis. The disease is usually presented with the 
rhinocerebral form and is characterized by the propensity of zygomycetes for vascular 
invasion and dissemination, commonly resulting in thrombosis and tissue necrosis. The 
infection can rapidly extend from the paranasal sinuses to the oral cavity, to the orbit and 
intracranially, sometimes producing cavernous sinus thrombosis.113 Zygomycosis almost 
always occurs among patients with a pre-existing immune defect, although rare cases have 
been reported among apparently normal individuals.114 In the majority of cases, the course 
is rapidly progressive and eventually fatal, unless prompt treatment with high doses of 
liposomal amphotericin B (LAmB), in association with careful and may be repeated surgical 
debridement, can change the otherwise dismal clinical course.  
Since the spectrum of diseases for which the use of immunosuppressive treatments, such as 
corticosteroids, cyclosporine, purine analogs (fludarabine, cladribine, nelarabin, 
pentostatin), rapamycin and mTOR inhibitors, various monoclonal antibodies (rituximab, 
bevacizumab, infliximab, basiliximab, Campath, etc) and allogeneic hematopoietic stem-cell 
transplantation has enlarged,115 and since the use of systemic antifungal prophylaxis with 
agents that are ineffective against zygomycetes, mainly azole derivatives has increased, 
zygomycosis appears to be an emerging threat the last two decades.116 Well-recognized 
predisposing factors for zygomycosis are diabetes mellitus (especially when complicated by 
ketoacidosis), treatment with corticosteroids, immunosuppression, prolonged leukopenia 
(neutropenia and lymphopenia), recent chemotherapy and tissue damage, history of 
allogeneic stem cell transplantation, chronic graft-versus-host-disease, and prolonged 
treatment with broad spectrum antibiotics and azole-type antifungal prophylaxis.  
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However, a common denominator of almost all of these conditions is the presence of 
excessive iron overload, either as high tissue iron burden, or as elevated serum Tf, and also 
as increased non-transferrin-bound iron.117 In particular, it has been suggested that diabetic 
ketoacidosis and acidoses of any aetiology predispose to zygomycosis by facilitating the 
dissociation of iron from iron-carrying proteins, thus providing increased available free 
iron.118 Elevated serum and tissue iron have a tremendous impact on the growth and 
development of zygomycetes.119 There are reports of fast Mucor growth, with formation of 
intra-arterial thrombi, among immunocompromised patients with iron overload.120,121 In a 
retrospective analysis of 263 allotransplanted patients, all five cases of invasive zygomycosis 
had significantly higher serum ferritin levels, Tf saturation, and number of previously 
transfused red blood cell units, as compared with matched controls. Zygomycetes possess a 
specific high-affinity iron permease gene (RFTR1), which has been characterized and 
cloned.122 Analysis of the polymorphisms of this gene, has recently been proposed as a tool 
for the molecular identification of the different zygomycete species.123 FTR1 is expressed 
during infection in diabetic ketoacidosis (DKA) and is required for full virulence of R.oryzae 
in mice. Disrupted FTR1 in multinucleated R. oryzae resulted in the inability of the fungus to 
segregate to a homokaryotic null allele. However, reduction of the relative copy number of 
FTR1-mRNA and inhibition of FTR1 expression by RNAi compromised the ability of R. 
oryzae to acquire iron in vitro and reduced its virulence in DKA mice. Importantly, passive 
immunization with anti-Ftr1p immune sera protected DKA mice from infection with R. 
oryzae.124 
The well-documented and repeatedly reported increased susceptibility to zygomycosis of 
haemodialysis patients, during treatment with DFO, an iron chelator that is capable of 
removing tissue iron, initially appeared to be a paradox.125,126 It became clear, however, that 
although DFO chelates iron, from the perspective of zygomycetes it is a xenosiderophore, as 
fungal siderophores have higher affinity for iron than DFO and therefore, are capable of 
easily and effectively detaching iron from it and providing it to the fungi.101,126 This ability is 
particularly prominent in zygomycetes, and these species can remove 8–40 times greater 
amounts of iron from DFO than A. fumigatus and C. albicans, respectively. The rapid and 
effective iron uptake by zygomycetes results in rapid growth in serum. The growth of 
Rhizopus rhizopodiformis spores, isolated from a dialysis patient with zygomycosis while on 
DFO therapy, was studied in an iron-deficient medium, containing human serum at 
increasing concentrations, enriched with different concentrations of ferrioxamine. A serum 
concentration of 40% inhibited fungal growth by >50%. However, in the presence of serum, 
ferrioxamine produced significant growth stimulation at 24 h that persisted at 48 h (Figure 
1).127 Data from animal models emphasize the exceptional requirement of iron for Rhizopus 
pathogenicity, since administration of DFO or free iron worsens the survival of animals 
infected with Rhizopus, but not with Candida.128 DFO can act as a xenosiderophore in 
Rhizopus, other members of the Mucorales, and probably other pathogenic fungi. It is 
assumed that fungal enzymes or siderophores are able to specifically bind to ferrioxamine 
and, because they have higher affinity for iron, strip iron from ferrioxamine and facilitate 
iron uptake by the fungi. A similar phenomenon does not take place with deferiprone.129 
The susceptibility of dialysis patients, treated with DFO, to zygomycosis could be attributed 
to the fact that uraemia results in significant retention of the iron-loaded ferrioxamine in the 
circulation, and that this is removed during dialysis, causing patients’ serum to lose its 
fungistatic power and be transformed to a favourable culture medium for zygomycetes.130 
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     Standard culture medium              +human serum 40%          +human serum +1 μƮ FeDFO    
Fig. 1. Spores of Rhizopus were cultivated for 24 h at 370C in standard culture medium 
BDM alone (A), in BDM with 40% human serum (B) or in BDM with 40% serum + 1 MM 
Fe.DFO (C). Lugol stain x 500. Reprinted from Boelaert J et al. J.Clin.Invest. 1993; 91: 1979-
1986. 
7.2 The role of newer iron chelators 
Since the mid-90’s additional orally administered iron chelators are available. There are two 
newer molecules, deferiprone (DFP, Ferriprox, Apotex), which was introduced in the 1990s, 
and deferasirox (DFX, Exjade, Novartis), which was introduced more recently.131 Both drugs 
are effective in clinical practice, but their use has not been associated with increased 
numbers of fungal infections and particularly, of zygomycosis. The reason for this 
discrepancy, as compared with DFO, may be the different chemical structure and chelating 
affinities of the three drugs. DFO is an exadentate chelator, has a higher molecular weight 
and shows a chelating relationship with the ferric iron of 1 : 1, which implies that each DFO 
molecule chelates one ferric ion. DFP is a bidentate chelator, and its chelating relationship is 
3 : 1, meaning that each ferric iron is chelated by three molecules of DFP. DFX is a tridentate 
chelator, and its chelating relationship is 2 : 1, meaning that each ferric iron is chelated by 
two molecules of DFX.132 The chemical structures of the three iron chelators are shown in 
Figure 2. 
The two newer iron chelators do not act as xenosiderophores, apparently because the fungal 
iron uptake systems are incapable of detaching iron from them. This could be due, either to 
inadequate molecular access, since they are smaller molecules than DFO, or to their higher 
affinity for iron, which means that DFP and DFX might form more stable chemical 
structures with iron, that are not destabilized in the presence of fungal enzymes or 
siderophores. Moreover, the demonstration of clear inhibitory activity of the two newer 
chelators on fungal growth suggests that these molecules are probably capable of detaching 
iron from the fungal iron uptake molecules and holding it more strongly.133 This has been 
proven in vivo, using animal models of zygomycosis, in which treatment of Rhizopus- 
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     Deferroxamine (DFO)               Deferasirox (DFX)                     Deferiprone (DFP)            
Fig. 2. Stereochemical structure and mocecular chelating relationship of the three available 
iron chelators. Deferroxamine (DFO) has higher molecular weight (MW) and is a 
hexadentate, i.e. each molecule holds one ferric iron (chelating ratio 1:1). Deferasirox (DFX) 
has lower MW and it is a tridentate, i.e. 2 DFX molecules hold each ferric iron (chelating 
ratio 2:1). Deferiprone (DFP) has even lower MW and it is a bidentate, i.e. 3 DFP molecules 
chelate each ferric iron (chelating ratio 3:1). 
infected mice or guinea pigs with DFP markedly improved survival.133 In cultures of 
Rhizopus oryzae, DFP has fungistatic activity at 24 h, confirmed at 48 h.129 The introduction of 
DFX and the recognition of the safety and efficacy profile of the drug encouraged its use in 
sporadic cases of systemic zygomycosis and in experimental animal studies. DFX induces an 
iron-starvation response in R. oryzae and activates RFTR1 expression. Addition of DFX to 
cultures of different members of the Mucorales produced a fungicidal effect, which was 
reversed by the addition of iron. The MIC90s of DFX against various Mucor spp. were much 
lower than the levels achieved by the administration of the usual daily dose of 20 mg/kg. 
Treatment with routine doses of DFX of diabetic ketoacidotic mice, infected with spores of 
R. oryzae led to significantly improved survival, as compared with controls, and resulted in a 
more than ten-fold reduction of brain and kidney fungal burden as compared with placebo-
treated animals. The kidneys of DFX-treated mice had no visible hyphae and there was an 
effective neutrophil inflammatory reaction, whereas kidneys of placebo-treated mice had 
extensive filamentous fungi and manifested a poor or complete absence of a neutrophil 
inflammatory response.134 In another experiment, mice infected intranasally with 107 spores 
of R. oryzae were treated for 7 days, starting 24 h post-infection, with either DFX 10 mg/kg 
twice daily or placebo. Similar to controls, infected or uninfected mice were treated with 
DFO 50 mg/kg. DFX was significantly more protective than placebo or DFO. As expected, 
DFO worsened the survival of infected mice, although it had no effect on uninfected mice. 
Treatment with DFX resulted in significantly increased Th1 and Th2 splenocyte 
subpopulations, and in significantly higher splenic and kidney levels of the 
proinflammatory cytokines TNF-ǂ and IFN-Ǆ, than those in mice treated with saturating 
iron or placebo.134,135  
8. Iron, protozoan and parasitic infections 
For the most intracellular protozoa, survival, growth and replication within the 
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acquisition from the host cells. These microorganisms elaborate elegant mechanisms for 
obtaining iron and transfer it into the iron-poor endophagosomal environment.   
Legionella pneumophila requires iron for optimal extracellular and intracellular growth. Some 
mutants are both, sensitive to the iron chelators and resistant to streptonigrin, an antibiotic 
which requires high levels of intracellular iron to exert microbicidal activity. These mutants 
were about 100-fold more sensitive than the wild type to treatment with DFO, indicating 
that they have defective intracellular iron acquisition and assimilation. This strain was 
unable to mediate any cytopathic effect and was impaired for infectivity of an amoebal 
host.136 L.pneumophila is engulfed into macrophages by macropinocytosis, and is not digested 
but proliferates intracellularly. Proliferation can be blocked by the Nramp1 protein, an iron 
transporter that reduces endolysosomal iron and confers resistance against invasive 
pathogens. However, inactivation of the PI3K pathway enhances Legionella infection and 
suppresses the protective activity of Nramp1. L.pneumophila abrogates phosphoinositide-
dependent fusion of macropinosomes with acidic vesicles, without affecting Nramp1 
recruitment. Thus Legionella escapes fusion with acidic vesicles and Nramp1-induced 
resistance to pathogens.137 
For any protozoan pathogen iron is an absolutely necessary nutrient to effectively grow and 
multiply. On the other hand many antiparasistic immune effector mechanisms of innate and 
adaptive immunity are orchestrated through iron deprivation. Incubation of human 
enterocyte cell lines with IFN-Ǆ and in vitro infection with the protozoan enteropathogen 
Cryptosporidium parvum resulted in the upregulation of IFN-Ǆ receptors and was followed by 
inhibition of the parasite growth and development. IFN-Ǆ mediated its action by inhibition 
of parasite invasion and by modification of intracellular Fe++ concentration, and this effect 
was partially reversed by inhibition of the JAK/STAT signaling pathway. IFN-Ǆ directly 
induces enterocyte resistance against C.parvum infection.138 
Toxoplasma gondii is an obligate intracellular parasite and a common opportunistic pathogen 
in HIV positive patients, and macrophage early nonspecific response is an important part of 
host defense. About 18 h following infection of mouse macrophages with a high burden of 
T.gondii tachyzoites, a strong down-regulation of the macrophage Tf receptor levels was 
observed. Stimulation of the mouse cells with toxoplasma lysate antigen had no effect on Tf 
receptor expression.139 IFN-Ǆ alone or in combination with IL-1, IL-6 or TNF-ǂ significantly 
inhibited T.gondii growth in murine astrocytes. However this inhibition appear not to be 
mediated through induction of ROS expression, or iron deprivation, but by other, as yet 
unclear mechanisms.140 
The in vitro growth of Pneumocystis Carinii can be easily suppressed by daphnetin (7,8-
dihydroxycoumarin) a well-known iron chelator, through iron deprivation in a dose-
dependent way. The inhibitory activity is not exerted when iron-repleted daphnetin is 
added to the culture system. Inhibition of P.carinii growth by daphnetin is associated with 
morphological changes, clearly determined by transmission electron microscopy.141 
Leishmania donovani uses another mechanism to obtain iron from the labile iron pool of the 
macrophages. As a consequence, intracellular macrophage iron is depleted, iron sensor, 
through IRP-1 and -2 is activated, mRNA of the Tf receptor-1 is stabilized and is transcribed, 
Tf receptor expression is upregulated and Tf uptake is increased. Then Leishmania easily 
retrieves iron from holotransferrin.142 L. donovani itself expresses a Tf receptor and their in 
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vitro growth is inhibited by iron chelators. Moreover, in vivo administration of DFO in mice 
infected with Leishmania leads to a slight delay in the development of cutaneous lesions. 
Unexpectedly however, systemic iron delivery at early time points of infection, decreased 
parasite load at the site of parasite inoculation, the regional lymph node, the liver and 
spleen. The protective effect of iron correlated with lower IL-4 and IL-10, but higher type-1 
cytokine transcripts (IFN-Ǆ and inducible ƯΟ synthase) at the site of inoculation, as well as 
by increased serum levels of IgG2a.143 An iron-dependent superoxide dismutase from 
Leishmania Chagas is expressed at low levels in the early logarithmic stage of development 
and increases at later stages of growth. The parasite demonstrates significant growth 
reduction when endogenous superoxide levels are increased, following the addition of 
paraquat in culture. There is a protective gene, LcFeSODB, which plays an important role in 
the parasite growth and survival by protecting the glycosomes from superoxide toxicity.144 
Malnutrition alters the innate immune response against L.donovani. Thus, diets deficient in 
calories, protein, and in the metal elements zinc and iron represent a risk factor for the 
development of visceral leishmaniasis, and in malnourished mice, a greater parasite burden 
is found in the spleen and liver, which is attributed to a failure of lymph node barrier 
function. Lymph node cells from the malnourished group produced increased levels of 
PGE2 and decreased levels of IL-10 and inducible NO synthase activity.145 Iron deficiency 
may finally favor the host and impair L.donovani growth. When iron availability is restricted 
the parasite’s growth may be reduced and the infection attenuated.146 
Another Leishmania spp, Leishmania amazonensis, elaborates an inducible ferrous iron 
transport system through LIT1, a novel parasitic membrane protein. LIT1 is only detectable 
upon intracellular invasion of the parasite and its expression is accelerated under iron-
deprived conditions. L. amazonensis lacking LIT1 protein abolishes its virulence and its 
replicating capacity within macrophages.147 
Trichomonas vaginalis is the most common non viral pathogen, transmitted sexually and is 
highly-dependent on iron. T. vaginalis is adhered to vaginal epithelial cells, through specific 
surface proteins (AP65, AP51, AP33 and AP23) named adhesins. Free iron, heme and 
hemoglobin induce AP65 mRNA and protein expression on the parasistic membrane, thus 
favoring virulence. Heme-induced AP65 expression was about 10-fold higher in a low-iron 
culture medium, indicating that T. vaginalis can use heme as an alternative source of iron, 
important to its growth and regulation of expression of the adhesin genes.148 An iron-
responsive promoter and other iron regulatory elements (IRE) in the 5'-UTR of the ap65-1 
gene, as well as two IRE-like hairpin-loop structures in mRNAs of TVCP4 and TVCP12 
cysteine proteinases, have been identified in T.vaginalis, suggesting the existence of a post-
transcriptional iron regulatory mechanism of critical genes by an IRE/IRP-like system in 
this protozoon.149 DFO killed all T.vaginalis isolates with a minimum lethal concentration of 
30 μM after 48 h of exposure, and a potent and persistent inhibitory effect of DFO on the 
parasite viability and growth was observed, with lower drug concentration and shorter time 
of exposure.150 
Tritrichomonas foetus is a protozoan pathogen of cattle, and its growth and virulence is 
greatly influenced by the iron concentration of the culture medium. In iron-restricted media 
both, Lf and Tf support T.foetus growth. However, a specific binding to the outer parasitic 
membrane has been demonstrated only for Lf, whose uptake at 370 C is about 3.5-fold 
higher, a finding indicating a mechanism of receptor-mediated endocytosis. In contrast, Tf 
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binding is nonspecific, and iron retrieval is achieved via extracellular release and 
siderophore assistance.151 Many microbial siderophores can also support T. foetus growth 
under iron-limited conditions, providing iron to ferredoxin, the major siderophore of the 
parasite. Iron uptake is not mediated by previous extracellular reduction, although T.foetus 
possesses some ferrireductase activity. Siderophores are pinocytosed by the parasites in 
small vesicles, exhibiting a very acidic environment. Hemin also supports T. foetus growth, 
probably with the involvement of heme oxygenase.152 Parasites grown in iron-depleted 
media exhibit reduced capability to destroy epithelial cell monolayers and reduced activity 
of several cysteine proteases, indicating that iron is an extracellular signal, modulating 
T.foetus’ ability to interact with host epithelial cells.153 In one study, mice inoculated 
intraperitoneally with a moderately- or a highly-virulent strain of T.foetus and treated with 
ferric citrate exhibited high mortality rate by the moderately-virulent strain up to the level of 
the highly-virulent strain. Peritoneal cultures showed that iron overload was associated 
with stimulation of parasite replication, which was strongly suppressed in untreated mice, 
and the less virulent strains showed lower efficiency for iron acquisition from Tf and other 
sources.154 
The greatest experience about the influence of iron metabolism on parasite growth has 
emerged from the study of malaria infection. Plasmodium grows up fluently in the 
intraerythrocyte environment, where plenty of iron, contained in hemoglobin, can be easily 
accessed and uptaken. Since about 3 decades ago there has been emerging evidence that, 
iron deprivation might represent an important mechanism in the battle of man against 
malaria.155 Asymptomatic parasitemia has been associated with the existence of 
hypochromic anemia, in the absence of a prominent acute phase reaction. These patients 
exhibit higher serum hepcidin concentration, higher ferritin, lower iron and transferrin 
levels, and lower transferrin saturation, and consequently have impaired intestinal iron 
absorption and dietary iron utilization. On the other hand malaria commonly coexists with a 
background of frank iron deficiency. Antimalarial treatment partly restores low-grade 
inflammation and decreases serum hepcidin, ferritin, and other indeces of inflammation, 
and should be preceded of any effort for anemia correction with iron. Clearance of 
parasitemia increases dietary iron absorption but did not affect systemic iron utilization. 
Therefore, in areas of high prevalence of malaria, since asymptomatic parasitemia has a 
protracted course, careful clinical evaluation of anemic patients is mandatory, because the 
unjustified or mistimed iron supplementation will be ineffective and may even be 
hazardous and render malaria symptomatic.156, 157 Among pregnant women in areas with 
high malaria prevalence, malaria parasitemia, hookworm infection, gravidity and advanced 
gestational age were associated with lower hemoglobin and iron deficiency. Malaria 
parasitemia, Ascaris lumbricodes and Trichuris trichiura infections and older age were 
associated with lower serum ferritin levels.158 
Intraerythrocytic malaria parasites digest hemoglobin to obtain the amino acids needed for 
their own protein synthesis. Hemoglobin degradation and total parasite protein content 
increase in parallel with parasite maturation, but the rate of hemoglobin degradation is 
higher, than the utilized amount of amino acids.159 Hemoglobin degradation yields also 
large quantities of ferriprotoporphyrin IX and iron, which create a highly oxidative 
erythrocyte environment and high requirements for detoxification. Redox-active iron 
released inside the erythrocyte, mediate the conversion of H2O2 to hydroxyl radical [HO]- 
which is more reactive. Superoxide dismutase (SOD) and nitroxide SOD detoxifies the 
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erythrocyte and acts similarly to the antimalarial drug 4-OH,2,2,6,6,tetramethyl piperidine-
N-oxyl (Tempol) in P.falciparum growth. Tempol inhibits parasite growth, and induces 
accelerated mortality in a SOD-overexpressing mouse model of malaria.160 SOD has 
therefore a protective role for the erythrocytes, and transgenic copper/zinc superoxide 
dismutase- - (CuZnSOD) mouse strains show higher sensitivity to infection by Plasmodium 
berghei. Moreover, treatment of infected erythrocytes, either SOD transgenic or normal, with 
oxidative stress inducers, reduces parasite viability. Therefore, CuZnSOD does not support 
plasmodium development, and impairment of its activity results in higher oxidative stress, 
favoring malaria growth.161  
Iron deficiency modulates Plasmodium yoelii development in hepatocytes, by inactivating 
hepatic xanthine-oxidase. Iron-deficient mice infected with Pl. yoelii sporozoites, exhibited 
enhanced development of hepatic stage, resulting in the earlier appearance of blood 
parasites. An iron-starving diet increased penetration of sporozoites into liver cells, whereas 
inactivation of hepatic xanthine-oxidase inhibited both, sporozoite penetration and schizont 
maturation. Moreover, inhibition of heme synthesis also results in inhibition of parasite 
development.162 Another mechanism, favorably influencing the clinical course of 
Pl.falciparum infection in iron deficient subjects, is the faster clearance of infected 
erythrocytes. Iron deficiency accelerates unifected erythrocyte death and enhances death 
and removal of infected erythrocytes by phagocytosis, which is evident from 
phosphatidylserine exposure. Indeed, parasitized iron deficient erythrocytes are more 
susceptible to phagocytosis in vitro, than normal erythrocytes.163,164 The importance of iron 
in plasmodium growth has shifted antimalarial treatment strategies and research towards 
the identification and application of new drugs intervening with the parasite iron 
metabolism. More details on the topic are mentioned in the following paragraphs. 
Trypanosomiasis or Chagas’ disease has been associated with iron overload. Trypanosoma 
possesses a unique mechanism of adaptation and iron acquisition from the host 
environment. Trypanosoma brucei escapes destruction by the host immune system, by 
regularly replacing its Variant Surface Glycoprotein (VSG) coat. The VSG is expressed together 
with expression site associated genes, encoding the heterodimeric Tf receptor. There are 
about 20 VSG expression sites and trypanosomes can change the active site, according to 
environmental conditions. Since the various Tf receptor genes, localized in different 
expression sites, differ somewhat in sequence, expression site switching results in the 
production of a slightly different Tf receptor. Trypanosomes can adapt the expression site of 
its Tf receptor to achieve the highest affinity for the host Tf molecule.165 
Hypochromic anemia is a dominant characteristic of this disease and its severity is 
correlated with the severity of trypanosomiasis. The parasite induces a strong type-I 
immune response, activating bone marrow and tissue macrophages and establishing an 
imbalance between erythropoiesis and erythrophagocytosis or erythroblastic apoptosis, 
which is the typical pathogenetic mechanism of anemia of chronic disease.166 In a murine 
model of trypanosomiasis, erythrophagocytosis by cytokine-activated M1 macrophages was 
the main initial cause of aggressive anemia during the acute phase of infection. Persistence 
of type I cytokine production in the chronic phase of infection perpetuates and deteriorates 
anemia. Meanwhile, iron homeostasis is perturbed and there is increased iron sequestration 
by macrophages, resulting after upregulation of Fp, Tf and ceruloplasmin genes, indicating 
that iron export is reduced. In the chronic phase of trypanosomiasis, iron sequestration 
worsens, while the enhanced uptake of iron-containing molecules is maintained.167 
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Entamoeba histolytica trophozoites can grow in vitro within culture media, containing 
ferrous or ferric iron, and they can use hemoglobin, holotransferrin, hololactoferrin and 
ferritin as iron sources. Iron-binding proteins are specifically bound to the amoeba surface, 
are uptaken by endocytosis, traffick through the endosomal/lysosomal route and are 
degraded by neutral and acidic cysteine-proteases. Tf and ferritin are mainly uptaken as 
clathrin-coated vesicles. However, apolactoferrin bound to membrane lipids and cholesterol, 
induces cell death. In vivo trophozoites secrete products capable to destroy enterocytes, 
erythrocytes and hepatocytes, releasing Tf, hemoglobin, ferritin and other iron-containing 
proteins, which, together with Lf derived from neutrophils and acinar cells, can be used as 
iron supplies by amoebas.168 Many biological functions and pathogenicity of the free-living 
amoeba Naegleria fowleri are dependent on the composition of the culture medium. The iron-
containing porphyrins hemin or hematin or the iron-free protoporphyrin IX, can support 
N.fowleri growth in serum free media, whereas iron-binding proteins, including hemoglobin 
cannot.169 Some growth-promoting factors for Entamoeba species are low molecular weight 
substances, found in cellular fractions of various cells, and are probably siderophores, such 
as ferredoxins and rubredoxin.170 
Hookworm infection has been associated with growth delay and iron deficiency anemia. In 
a mouse model of this disease, infected animals, fed with a standard diet exhibited 
significant growth delay and reduced hemoglobin levels, compared to uninfected controls, 
whereas no significant difference in weight or hemoglobin concentration was observed 
between infected and uninfected animals, fed with an iron-restricted diet. Moreover, iron-
restricted animals exhibited reduced intestinal worm burden, compared to animals fed with 
the standard diet. Finally, infected animals fed with intermediate-iron containing diet 
exhibited greater weight loss and anemia, than animals fed with iron-restricted- or high-iron 
diets. Mortality was also higher in the intermediate-iron containing diet. Therefore, severe 
dietary iron restriction impairs hookworm development, but moderate iron restriction 
enhances host susceptibility to severe disease.171 
The human blood fluke Schistosoma japonicum is responsible for significant morbidity and 
mortality in tropical areas. For this fluke and some other invertebrates, an additional role for 
iron has been postulated, and this concerns the stabilization of the extracellular matrix. 
Schistosoma requires iron for its development and stores abundant iron in the vitelline 
(eggshell-forming) cells of the female system, in the form of yolk ferritin that is upregulated 
in females and is also expressed at low levels in egg-stages and adult males. Iron 
concentrations have been found higher in the female- than the male adult parasite, but also 
in the parasite eggs and purified eggshell, whose matrix is composed of heavily cross-linked 
eggshell precursor proteins.172 
9. Clinical considerations - infections in iron overloaded patients 
As previously noted, iron is crucial for the growth and proliferation of all microorganisms, 
due to its role in mitochondrial respiration and DNA synthesis. Iron starvation and 
oxidative stress are the hurdles that bacteria must overcome to establish an infection. In 
some cases there is excess iron available and specific infections are more common. Iron 
overload may be secondary to lysis of red cells from free heme compounds, as a result of 
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In the presence of hemolytic disorders, caused by malaria or Bartonella bacilliformis (in cases 
of Oroya fever) salmonella infections are noted.173 The presence of free hemoglobin or heme 
may effectively impair or completely destroy the mechanism of natural resistance. Bullen et 
al. showed that ferric citrate, hematin hydrochloride, lysed guinea-pig red cells and 
crystalline human hemoglobin greatly enhanced E. coli virulence, when injected 
intraperitoneally into normal guinea-pigs.174 
Blood transfusions may increase the free hemoglobin. Red blood cell transfusions should be 
used sparingly, keeping in mind the potential risks of infection and poor outcomes in 
critically ill patients. In a prospective, observational cohort study by Taylor et al. the 
posttransfusion nosocomial infection rate was 14.3% in 428 evaluable patients, significantly 
higher than that observed in nontransfused patients (5.8%; p <0.0001).175 In a multivariate 
analysis controlling for patient age, maximum storage age of red blood cells, and number of 
red blood cell transfusions, only the number of transfusions was independently associated 
with nosocomial infection (odds ratio 1.097; p=0.005). In addition mortality and length of 
stay (in intensive care unit and hospital) were significantly higher in transfused patients, 
even when corrected for illness severity.176 Secondary analysis of a multicentered, 
prospective observational study of transfusion practice in intensive care units in the United 
States showed that transfusion of packed red blood cells increases the risk of developing 
VAP (ventilator associated pneumonia). The effect of transfusion on late-onset VAP was 
more pronounced (odds ratio 2.16; 95% CI, 1.27-3.66) and demonstrated a positive dose-
response relationship.177 To determine whether blood transfusion influences infection after 
trauma, Agarwal et al. analyzed data on 5366 consecutive patients, hospitalized for more 
than 2 days. Even when patients were stratified by Injury Severity Score, the infection rate 
increased significantly with the higher numbers of transfused blood units. Blood transfusion 
in the injured patients is an important independent statistical predictor of infection. Its 
contribution cannot be attributed to age, sex, or the underlying mechanism of severity of 
injury.178 Both, modified and native human hemoglobin may promote infection.179 They 
showed that pyridoxalated polymerised human hemoglobin promotes fulminant E. coli 
septicemia in mice, which draws attention to the potential danger of such products in the 
clinic. 
Hereditary hemochromatosis is the prototype disease for primary iron overload. Vibrio 
vulnificus has been linked to primary sepsis, which usually occurs in patients with 
underlying liver disease (cirrhosis or hemochromatosis).180 Although this pathogen can be 
destroyed by human plasma, it multiplies rapidly when free iron is available. After eating 
raw sea food, like oysters, the patient develops high fever, prostration, hypotension and in 
most cases characteristic cutaneous manifestations (initially erythematous patches followed 
by ecchymoses, vesicles and bullae) with a mortality rate up to 50% without the prompt 
therapy. Primary hemochromatosis was the commonest underlying disease in patients with 
liver abscesses caused by Yersinia enterocolitica.181 Some Yersinia strains are unable to 
synthesize siderophores but they can exploit host-chelated iron stores and the drug DFO. As 
a result, iron overload appears to be independent risk factor for Y. enterocolitica bacteremia, 
mainly by the serotypes O:3 and O:9. Yersinia bacteremia must be considered as an indicator 
of possible iron overload and Yersinia infection must be suspected in febrile 
hemochromatosic patients. In the past, patients with chronic renal failure, undergoing 
dialysis received multiple transfusions and frequent parenteral iron preparations. In a study 
by Boelaer Yersinia bacteremias (Y. enterocolitica and Y. pseudotuberculosis) were detected 
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more often when ferritin levels were >500 ng/ml.182 Y. enterocolitica has also been identified 
as a causative agent of posttransfusion septic shock. Yersinia bacteremias complicate the 
transfusions of blood that has been stored for more than 3 weeks.183,184 The high-
pathogenicity island (HPI), present in pathogenic Yersinia and encoding the siderophore 
yersiniabactin, has been found in E. coli pathotypes, responsible for bacteremias, neonatal 
meningitis and urosepsis.185 
The spleen, an important part of the reticuloendothelial system, acts as a filter for circulating 
debris, including bacteria and as an important source of lymphoid cells and antibody 
production. Splenectomy may alter the ability to prevent or suppress some infections. There 
appears to be a high risk of severe bacterial infections when splenectomy is performed in 
patients with thalassaemia major, hepatitis, cirrhosis, histocytosis or inborn errors of 
metabolism.186,187 Seventy three patients with ǃ-thalassemia/HbE were studied 1-28 years 
after splenectomy. Serum ferritin levels in both, HbH and ǃ-thalassemia/Hb E patients were 
higher than normal. They were higher in ǃ-thalassemia/HbE than HbH disease. Most 
striking was the significantly higher serum ferritin levels in splenectomized patients with ǃ-
thalassemia/HbE disease than in the nonsplenectomized ones. After splenectomy, in 
patients with ǃ-thalassemia/HbE disease, there was an increase of the Tf saturation in 
addition to increased circulating non-trasferrin bound iron.188 
Levels of serum iron are elevated in patients undergoing hematopoietic stem cell 
transplantation (HSCT), as a result of disturbed iron metabolism, pre-transplantation blood 
transfusions, or cytotoxic therapy, for conditioning before HSCT. The complications of iron 
overload in HSCT patients include bacterial and fungal infections, mucositis, chronic liver 
disease (fibrosis progression), sinusoidal obstruction syndrome, and other regimen-related 
toxicities. Iron overload can be considered as an independent adverse prognostic factor in 
allogeneic HSCT. Screeneing for iron overload at various time points before and after 
transplantation may be beneficial especially in patients with thalassemia and 
myelodysplastic syndromes.189 
Singh et al, assessed the role of hepatic explant iron overload as a risk factor for Staph. aureus 
bacteremia in liver transplant recipients. Noncarriers (patients without S. aureus nasal carriage) 
who developed S. aureus bacteremia were more likely to have hepatic iron overload. A 
quantifiable assessment of hepatic iron in patients without carriage at the time of 
transplantation can potentially identify those who may be at risk for early S. aureus 
bacteremia.190 In healthy humans the lower respiratory tract as well as all mucosa, contains a 
very low free iron concentration (10-18 M), while in cystic fibrosis (CF) patients, sputum iron 
concentration is very high, showing a median value of 63x10-6 M. Accumulation of catalytic 
reactive iron contributes to subsequent clinical complications in the lung disorders by the 
production of ROS and increases bacterial growth and virulence. The iron-overload of the 
sputum of CF patients induces nonmotile forms, aggregation and biofilm formation both in 
Pseudomonas aeruginosa and Burkholderia cenocepacia which are the main pathogens in these 
patients, facilitating the penetration of host epithelial barriers and contributing to the 
establishment of infection, colonization, persistence and systemic spread of these pathogens.191 
In human plasma, a fall in Eh (oxidation-reduction potential) or pH results in the abolition 
or marked reduction of its bactericidal properties. This is highly relevant to infection after 
trauma, where a fall in Eh and pH frequently accompanies tissue damage. Hypoxia 
interferes with the oxidative killing of many bacteria by polymorphonuclear leukocytes. In 
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addition it produces a fall in tissue Eh and as a result free ferrous iron is produced, leading 
to overwhelming growth of bacteria. If the Eh is lowered, the ferric iron is reduced to the 
ferrous form, no longer bound to Tf.   
The bactericidal power of fresh human plasma against Klebsiella pneumoniae and E. coli is 
extremely sensitive to changes in Eh and pH. At a high Eh (approx. +200 mV) the bacteria 
were destroyed, but rapid regrowth was observed when the Eh was lowered to -400 mV. 
Abolition of the bactericidal effect was also produced by adding ferric iron at a high Eh 
(approx. +200 mV). Lowering the pH to 6.5 reduced or prevented the bactericidal effect. 
Rising the Eh from –400 to +200 mV restored the bactericidal effect.192 Some bacteria like Cl. 
Perfringens or E. coli have developed reducing systems. They may take advantage of a 
reduction in skin Eh and they are capable of lowering the Eh of tissue fluids to a level where 
Fe2+ is freely available. These results are probably related to the availability of iron for 
bacterial growth, and could be important for understanding the development of infection in 
injured or diseased tissue. Iron supplementation to treat anemia is controversial, since it may 
promote the progression of the underlying infectious disease but existing data are 
insufficient to support this hypothesis.193 
10. Iron chelators as adjuvant treatment in systemic fungal and protozoan 
infections 
It is self-evident if we take into consideration all the above, that an important weapon in the 
war against the various infectious microorganisms might be iron deprivation. Many efforts 
have been performed for this task, in targeting the appropriate microbial pathway, 
identifying the ideal compound for each microorganism, evaluating its efficacy, confirming 
its safety and testing its clinical usefulness. The usually acute clinical course of bacterial 
infections, the abundance of antibiotics and the relative satisfactory handling has restricted 
research programs testing iron chelators for fungal and protozoan infections and 
infestations. 
Among fungal infections the most challenging is zygomycosis, for which effective treatment 
is still unavailable. Many studies, elaborating animal models for this disease have tried to 
address the efficacy of iron chelating agents, against this mycosis. In a mouse model of 
zygomycosis, animals were infected with R. oryzae spores, and 24 h later were treated with 
DFP at dose levels of 50, 100 or 200 mg/kg every day or every other day. The dose of 100 
mg/kg every other day resulted in a significant survival advantage of DFP-treated mice, as 
compared with placebo-treated animals. The other dose schedules were either ineffective or 
toxic. The survival advantage was comparable to, although lower than, that of Liposomal 
Amphotericin-B (LAmB)-treated mice. Both drugs significantly reduced the brain fungal 
burden as compared with placebo. The beneficial effect of DFP was abrogated when animals 
were given ferric chloride.133 In a similar mouse model of established zygomycosis, the 
administration of DFX was associated with comparable efficacy to that of LAmB. DFX has 
shown efficacy in neutropenic and diabetic ketoacidotic mice with zygomycosis. In these 
experiments, DFX at a daily dose of 20 mg/kg, starting 24 h after infection was synergistic 
with LAmB at a high-dose schedule of 15 mg/kg daily, in the reduction of fungal burden 
from the brain and the kidney. Moreover, the combination of the two drugs significantly 
improved survival time as compared with placebo or each drug separately.134 Similar results 
have been obtained with the combination treatment in a mouse model of aspergillosis.135  
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The use of iron chelators as adjuvant treatment in systemic zygomycosis and other mycoses 
appears to be rational, and has been shown to be effective in sporadic cases. Reed et al. 
reported a case of a 40-year-old diabetic patient with aggressive rhinocerebral zygomycosis 
and progressive central nervous system involvement, despite combination treatment with 
high-dose LAmB plus caspofungin and surgical debridement. As brain magnetic resonance 
imaging (MRI) showed new parenchymal lesions and left cavernous sinus thrombosis, he 
was given a 7-day salvage treatment with DFX 1000 mg daily. A new brain MRI scan 
showed significant improvement, and treatment with LAmB was discontinued. The patient, 
4 months later, remained in good condition without any neurological deficit. This is the first 
reported case of zygomycosis being successfully treated with a combination of classical 
antifungal treatment and an iron chelator.194 We have recently treated two patients with 
acute lymphoblastic leukemia in remission (one of them following allogeneic 
transplantation) with zygomycosis (one with concurrent rhinocerebral and pulmonary form, 
the second with classical rhinocerebral form) with a combination of LAmB 10 mg/kg, 
posaconazole and DFX 20 mg/kg daily. Restricted intranasal and intrasinus surgical 
debridement was also applied repeatedly. Both patients responded very well, with rapid 
defervescence, resolution of pain and chymosis, and disappearance of the dense pulmonary 
and sinonasal infiltrates (unpublished data). Some more published cases have also shown 
encouraging results195 however in other cases, iron chelation treatment was unsuccessful.196  
Therefore, the possible benefit of iron chelation as adjuvant treatment in systemic mycoses, 
and particularly in zygomycosis, had to be tested in a prospective randomized trial. Such a 
clinical trial, the DEFEAT mucor study, investigated the existence of synergy between the 
classical treatment plus or minus DFX. Twenty patients with proven or probable 
zygomycosis were randomized to receive LAmB plus DFX (20 mg/kg/day for 14 days) or 
LAmB plus placebo. Surprisingly, death was more frequent in the DFX than in the placebo 
arm and global success was worse for the DFX arm, since patients of this arm had higher 
mortality rate at 90 days. This was attributed to population imbalances between the two 
arms, and therefore, make generalizable conclusions cannot be drawn.197  
DFO, although is a xenosiderophore for Zygomycetes, may have direct and irreversible toxic 
effects on P.carinii, independently of iron chelation. This direct and irreversible damage of 
P.carinii by DFO was confirmed in vivo, in an animal model, in which a once-a-week aerosol 
treatment of PCP with DFO was effective in 100% of the animals, both as a prophylactic and 
as a curative treatment.198 
All the available iron chelators can inhibit the growth of malaria parasites. Using a flow 
cytometric method for testing in vitro drug susceptibility of Pl.falciparum to 
hydroxypyridinone derivatives and to DFO, it has been found that both classes of chelators 
exhibited dose-dependent inhibition of parasite growth, but DFO demonstrated a stronger 
inhibitory effect. The MIC required for the parasite growth, correlated with observed 
abnormal microscopic morphology, and sensitivity to iron chelators was shown for both, 
chloroquine- and pyrimethamine-resistant parasites.199 In another study, comparing the 
efficacy of DFO and DFX at 30 μM/l or 60 μƮ/l, added in cultures of Pl. falciparum in 
human erythrocytes, it was observed that DFX had marked antimalarial activity by 6 h after 
exposure, and over 48 h of culture, and although the IC50s were similar for DFX and DFO, 
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Dexrazoxane is an iron chelating prodrug, used for the protection of anthracyclin-induced 
cardiotoxicity, which must undergo intracellular hydrolysis to bind iron. Investigating the 
antimalarial properties of dexrazoxane on Pl. falciparum cultured in human erythrocytes, 
and on P.yoelii cultured in mouse hepatocytes, it was found that dexrazoxane inhibited P. 
falciparum growth, only at suprapharmacologic concentrations. In contrast, pharmacologic 
concentrations of dexrazoxane inhibited P.yoelli growth by 45-69%, implying the presence of 
a dexrazoxane-hydrolyzing enzyme in hepatocytes but not in erythrocytes or malaria 
parasites.201 Novel aroylhydrazone and thiosemicarbazone iron chelators exhibit strong 
inhibitory activity on cultured tumor cells. These compounds were tested as antimalarials 
on chloroquine-sensitive- and -resistant strains of Pl. falciparum, and were significantly more 
active in both strains than DFO. The anti-malarial activity correlated with anti-proliferative 
activity against neoplastic cells. This class of lipophilic chelators may be potentially useful 
agents as anti-malarials.202 Among various other synthetic siderophores the most promising 
profile (low MIC for plasmodia and minimum toxicity to mammalian cells) was 
demonstrated by an acylated monocatecholate or a triscatecholate as substituent.203 To 
examine the site of action of antimalarial iron chelators, Loyevsky et al. have shown that 
specific fluorescence indicating the presence of iron chelators was observed within the 
parasites, implying that iron chelators bind labile iron within the plasmodium.204 
The antimalarial activity of zinc-desferrioxamine (Zn-DFO) was found to be superior to that 
of DFO in vitro. A possible explanation is that the complex Zn-DFO might be more easily 
permeable into parasitized erythrocytes, exchange zinc for ferric ions due to higher affinity 
and deprive iron from the parasite. Parasites treated with Zn-DFO were less likely to 
recover at a later stage, in comparison to parasites treated with DFO, therefore, the complex 
Zn-DFO, which is more effective in vitro, should be examined for its in vivo activity.205 
Many iron chelators are very effective in the treatment of trypanosomiasis and almost as 
effective as benznidazole, the classical drug used for the treatment of this disease. Some of 
them inhibit T.Cruzi growth at very low concentrations, thanks to their ability to interfere 
with and disrupt essential steps of epimastigote iron, copper or zinc metabolism at 
intracellular sites.206 Eleven out of 13 other iron chelators inhibited trypanosoma growth in 
vitro, but many of these chelators were also cytotoxic for human HL-60 cells and therefore 
were not further tested. Newer, more specific, lipophilic iron-chelators may serve as lead 
compounds for novel anti-trypanosomal drug development.207 Bloodstream forms of 
T.brucei are 10 times more sensitive than mammalian cells to iron depletion, and treatment 
with DFO inhibits parasite proliferation, inducing inhibition of DNA synthesis and decrease 
in oxygen consumption, findings implying that DFO impairs ribonucleotide reductase and 
alternative oxidase activity, apparently by chelating cellular iron and preventing its 
incorporation into the newly synthesized apoproteins. DFO treatment for 24 h has no effect 
on superoxide dismutase activity.208 Three compounds of an aminothiol family of iron 
chelators were tested against Trypanosoma Cruzi. BAT-TE completely arrested the growth of 
trypomastigote forms in mouse blood, while BAT-TM arrested growth in T.cruzi-infected 
mice. These results render BAT derivatives potential candidates for the clearing of donated 
blood from trypomastigotes in endemic areas.209 
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